{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    8,
    9,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    27,
    28,
    29,
    35
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Rescreening Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.5",
        "sectionTitle": "Repeat Testing and Subject Rescreening",
        "description": "Reference for procedures regarding subjects who fail protocol-specified screening criteria."
      },
      {
        "id": "ref_2",
        "name": "Adverse Events Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "12.3.1",
        "sectionTitle": "All Adverse Events",
        "description": "Reference for routine preventative foot care and early intervention for foot problems."
      },
      {
        "id": "ref_3",
        "name": "Informed Consent Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "16.2.3",
        "sectionTitle": "Informed Consent",
        "description": "Details regarding optional prescreening-specific or full informed consent."
      },
      {
        "id": "ref_4",
        "name": "Pretreatment Phase Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.1.2",
        "sectionTitle": "Pretreatment Phase",
        "description": "Reference for additional albuminuria/proteinuria measures."
      },
      {
        "id": "ref_5",
        "name": "Safety Evaluation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.5.1",
        "sectionTitle": "Safety Evaluation",
        "description": "Reference for safety evaluation procedures."
      },
      {
        "id": "ref_6",
        "name": "Concomitant Therapy Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8",
        "sectionTitle": "Prestudy and Concomitant Therapy",
        "description": "Reference for disallowed therapies and recording of medications."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Janssen Research & Development is a global organization that operates through different legal entities in various countries. The term 'sponsor' is used throughout the protocol to represent these various legal entities.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Title Page",
        "pageNumber": 1
      },
      {
        "id": "annot_2",
        "text": "Double-blind study drug should be permanently discontinued for any subject who experiences a serious adverse event of biochemically-confirmed DKA, has his/her treatment allocation formally unblinded by the investigator, or undergoes a renal transplant or initiates maintenance dialysis.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "10.2.1 Study Drug Treatment Premature Discontinuation",
        "pageNumber": 7
      },
      {
        "id": "annot_3",
        "text": "For fasting plasma glucose and lipids, subjects must be fasting for at least 8 hours before blood sample collection, except for the screening visit when nonfasting blood samples may be collected.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Time and Events Schedule (Footnote r)",
        "pageNumber": 29
      },
      {
        "id": "annot_4",
        "text": "While positive reagent strip analysis (eg, dipstick â‰¥2+) may be suggestive of albuminuria/proteinuria that meet the prescreening criteria, any positive reagent strip findings must be accompanied by one of the specified albuminuria/proteinuria prescreening measures.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "3.1 Overview of Study Design (Prescreening)",
        "pageNumber": 14
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "9.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-09-06",
        "description": "Primary reason for amendment is to decrease the number of primary composite events required for the interim analysis from 540 to 405.",
        "amendmentNumber": "Amendment INT-6"
      },
      {
        "id": "ver_2",
        "versionNumber": "Not Specified",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2016-05-06",
        "description": "Include new safety information and guidance regarding subject management surrounding the event of lower extremity amputations.",
        "amendmentNumber": "Amendment INT-5"
      },
      {
        "id": "ver_3",
        "versionNumber": "Not Specified",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2016-01-19",
        "description": "Sample size expansion and removal of eGFR cap for subjects >=60 to <90 mL/min/1.73m2.",
        "amendmentNumber": "Amendment INT-4"
      }
    ],
    "summary": {
      "referenceCount": 6,
      "annotationCount": 4,
      "versionCount": 3
    }
  }
}